Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

• Published in: BMC medicine Vol. 17; no. 1; p. 8
• Main Authors: Gavilá, Joaquín, Oliveira, Mafalda, Pascual, Tomás, Perez-Garcia, Jose, Gonzàlez, Xavier, Canes, Jordi, Paré, Laia, Calvo, Isabel, Ciruelos, Eva, Muñoz, Montserrat, Virizuela, Juan A, Ruiz, Isabel, Andrés, Raquel, Perelló, Antonia, Martínez, Jerónimo, Morales, Serafín, Marín-Aguilera, Mercedes, Martínez, Débora, Quero, Juan C, Llombart-Cussac, Antonio, Prat, Aleix
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 09-01-2019; BioMed Central; BMC
• Subjects: Adjuvant chemotherapy; Adult; Aged; Anopheles; Anthracyclines; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Breast cancer; Breast Neoplasms - drug therapy; Cancer; Cancer metastasis; Cancer therapies; Cancer treatment; cardiac safety; Cardiotoxicity - epidemiology; Chemotherapy; Chemotherapy, Adjuvant - adverse effects; Chemotherapy, Adjuvant - methods; Confidence intervals; Congestive heart failure; Dosage and administration; Doxorubicin; Doxorubicin - administration & dosage; Doxorubicin - adverse effects; Doxorubicin - analogs & derivatives; Drug therapy; Enrichment; ErbB-2 protein; ESR1 protein; Female; Gene expression; Genes; Heart failure; Heart rate; Hematology; HER2; HER2-enriched; Heterogeneity; Humans; Immunotherapy; Independent variables; intrinsic subtypes; Metastasis; Middle Aged; Monoclonal antibodies; Neoadjuvant Therapy - adverse effects; Neoadjuvant Therapy - methods; Paclitaxel; Paclitaxel - administration & dosage; Paclitaxel - adverse effects; PAM50; Patients; Pertuzumab; Polyethylene Glycols - administration & dosage; Polyethylene Glycols - adverse effects; Receptor, ErbB-2; Safety; Safety and security measures; Surgery; Targeted cancer therapy; Trastuzumab; Trastuzumab - administration & dosage; Trastuzumab - adverse effects; Tumors; Ventricle; PAM50; neoadjuvant; Breast cancer; HER2-enriched; HER2; cardiac safety; intrinsic subtypes
• ISSN: 1741-7015; 1741-7015
• DOI: 10.1186/s12916-018-1233-1

Keywords: Breast cancer, PAM50, HER2, intrinsic subtypes, cardiac safety, HER2-enriched, neoadjuvant